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Summary.-Cells from 3 human tumours have been grown in soft agar contained in
Millipore diffusion chambers and implanted i.p. in mice. Clonal growth was obtained
from fresh biopsy samples, from cryopreserved tissue, and from xenografts of the
tissues in immune-suppressed mice. The radiosensitivities of a melanoma and an
ovarian carcinoma were evaluated by in vitro irradiation before assay for colony
formation. Xenografting did not modify the radiosensitivity of the melanoma. Cells
from another tumour were exposed to Adriamycin or cyclophosphamide whilst con-
tained within i.p. diffusion chambers; the sensitivity was similar for cryopreserved
and xenografted cells. The results encourage further attempts to quantify the sensi-
tivity of human tumour cells by these methods.
THE DIRECT MEASUREMENT of the sensi-
tivity ofhuman tumour cells to drugs and
radiation is an important objective. Exten-
sive studies of clonogenic cell survival
have been made in experimental tumours,
but studies on human cells have been
limited largely by lack of the necessary
assay techniques. Recent work in this
laboratory has produced 3 clonogenic
assays that are applicable to human tu-
mour cells: an in vitro replenishable soft-
agar assay (Courtenay et al., 1976;
Courtenay & Mills, 1978), ain i.p. agar
diffusion chamber (ADC) assay (S*mith
et al., 1976) and a lung colony assAy in
immune-deprived mice (Thomas, 1979;
Selby & Thomas, 1980). These have mostly
been applied in examining the chemo-
sensitivity and radiosensitivity of xeno-
grafted human tumours, but clonal growth
of cells taken from patients has also been
obtained (Courtenay et al., 1978). The
present paper describes our first attempts
to use the ADC assay to determine cell-
survival curves after drug treatment or
irradiation of human cells that have not
been xenografted.
Alternative in vitro clonogenic assays
have been described by Hamburger &
Salmon (1977). These have been used to
estimate the sensitivity of clonogenic
human tumour cells to drug therapy in
vitro, and encouraging correlations with
clinical responses are reported (Salmon
et al., 1978; Alberts et al., 1980). Their
studies were limited to single experiments,
and plating efficiencies (PE) were often
low. The present study was restricted to
samples with PEs of more than about 10%
and cryopreservation allowed repeated
experiments and an assessment of the
reproducibility ofresults.
There is now some evidence that xeno-
grafted human tumours may retain the
chemosensitivity of their original tumour
(Giovanella et at., 1978; Shorthouse et at.,
1980). Most ofthese studies have compared
tumour-volume responses in the xeno-
grafted tumours with clinical responses in
the patient. We have here compared the
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measurement ofcell survivalin the original
tumour with those in the early-passage
xenografts, which provides an alternative
approach to this question.
MATERIALS AND METHODS
Tumours and cryopreservation.-Tumour
samples from 3 patients were used in this
study (Table I). The 2 solid tumours were
immersed in Ham's F12 medium at 4°C
immediately after removal, and transported
to the laboratory. They were washed in
medium, dissected free of necrotic material,
and cut into 2mm cubes. S.c. implants ofthe
cubes were made bilaterally into 5 CBA/lac
mice, immune-suppressed by thymectomy,
cytosine arabinoside pretreatment and 9 Gy
whole-body irradiation (Steel et al., 1978;
Selby et al., 1980). The xenograft lines
so established (HX47 and 49) were serially
transplanted in a similar manner.
Ascitic fluid containing malignant ovarian
carcinoma cells from Patient B was cooled to
40C and transported to the laboratory. The
cells were washed and resuspended in Ham's
F12 medium with 20% added special Bobby
Calf Serum (Gibco). Cells were counted using
a phase-contrast microscope, and bright cells
which excluded lissamine green were regarded
as viable. 106 cells were implanted i.m. or
s.c. into 10 immune-suppressed CBA mice,
but none ofthese implants grew.
Tumour pieces and cells from ascites
(107 cells/ml) were suspended in Ham's F12
medium with 20% Bobby Calf Serum and
10% dimethylsulphoxide, cooled at 10C/min
for 30 min followed by 2°C/min for 1 h, and
stored over liquid N2.
Colony growth.-Frozen ampoules were
thawed rapidly in a water bath at 37°C and
thetumourpieces orcellsimmediately washed
x3inmediumtoremovedimethylsulphoxide.
Cell suspensions were prepared by mechanical
disaggregation of tumour pieces both after
cryopreservation and from xenograft lines.
Cells were counted under phase-contrast with
lissamine green.
Colony growth from cell suspensions was
assayed by the agar diffusion chamber
(ADC) assay according to the method of
Smith et al. (1976). In brief, the cells were
suspended in medium containing 0.3% agar
and injected into Millipore diffusion cham-
bers. Rat red blood cells (1:35 dilution of
TABLE I.-Source of tumour material
Patient Tumour
A Subcutaneous
metastasis of
melanotic melanoma
B Ascites from a poorly
differentiated papillary
serous eystadeno-
carcinoma ofovary
C Peritoneal metastasis
ofan undifferentiated
polygonal-cell cancer
ofuncertain primary
site
Subse-
quent
xeno-
graft
line
desig-
nation
Treatment
before
tumour
removed
from
patient
HX47 None
Chlorambucil,
None Treosulphan,
Cyclophosph-
amide,
Vincristine,
Adriamycin,
5FU
HX49 None
whole blood) were added to the tumour cell
suspensions from Patients B and C as well as
from HX47 and HX49. The chambers were
incubated in the peritoneal cavities of pre-
irradiated C57BL mice (1 chamber/mouse)
for 3 weeks and colonies scored under a dis-
secting microscope. At least 6 mice were used
for each experimental point.
Cytotoxic treatment.-Cell suspensions of
ovarian ascites (Patient B), malignant mela-
noma (Patient A) and the xenograft HX47
were irradiated in vitro under aerobic condi-
tions at room temperature in polystyrene test
tubes using 60Co y irradiation at a dose rate
of 5 Gy/min. Tumour cells from Patient C
and the corresponding xenograft (HX49)
were suspended in medium with soft agar and
injected into diffusion chambers. These
chambers were implanted into the abdominal
cavities of normal male C57BL mice (2
chambers/mouse) which within a few hours
were then treated with i.v. injections of
Adriamycin (Montedison) or cyclophospha-
mide (Endoxana, WB Pharmaceuticals). The
treated chambers were transplanted after
18 h into the peritoneal cavities of pre-
irradiated C57BL mice (1 chamber/mouse)
and colony growth assayed. This method of
tumour-cell treatment, referred to as the
"ADC exposure system" has previously been
used for drug treatment of human marrow
cells and human tumour xenograft cells
(Selby et al., 1980).
Colony analysis.-Colonies were studied by
histology, immunofluorescence and electron
144SURVIVAL OF CRYOPRESERVEI) TUAIOUR CELLS
microscopy, using techniques previously des-
cribed (Selby et al., 1980a).
RESULTS
Colony growth was assayed for each of
the tumour samples at the time of biopsy,
after cryopreservation and, in the case of
HX47 and HX49, after growth as xeno-
grafts for up to 5 passages. The PEs are
shown in Table II. There was a linear
TABLE II. Plating efficiency in agar
diffusion chamibers
PIE v-
P)atient
A
B
C
Xenio-
graft
(lesig-
nation
HX47
HX49
Origiial
biopsy
sample
0.9
1-7, 3-0t 9.)
After
cryo-
preser- XenIo-
vatioIl graft
1.9 3-5-18+
2-8 + 0.6* None
:12+1*4 3-6++
* +s.d.
t Two separate samples.
+ Increase witlh serial passage (see Selby et atl.,
1980(o).
relationship between the number of cells
plated and the number of colonies growing
for all tumours.
Cells in colonies were compatible with
their tumours oforigin in morphology and
histological appearance in sections cut
through fixed colonies. The ultrastructure
of cells in colonies from HX47 and direct
from Patient C were compatible with their
tumours of origin. Further details of the
electron microscopic appearance of colo-
nies from xenografts have already been
reported (Selby et al., 1980a).
The in vitro radiation dose-response
curve of cryopreserved ovarian ascites
cells (Patient B) is shown in Fig. 1. Loga-
rithmic linear-regression analysis ofpoints
on the exponential part of the curve gave
Do 1-47 Gy (95%o confidence limits 1P20-
1.89) with an extrapolation number of 30.
In 4 experiments the cells were irradiated
immediately after thawing, but similar
results were obtained in one experiment
in which the cells were incubated at 37°C
.,1
m~/ 001
5 10
Radiation Dose (Gy)
FIG. 1.-Cell survival after irradiation int
vitro of ovarian carcinoma ascites (Patient
B). Cells wvere taken directly by para-
centesis anid cryopreserv-ed in liquid N2. In
4 experiments cells were irradiated imme(di-
ately after thawing (0). In 1 experiment
cells were cultured for 12 h before irradii-
ation (0). Eachi point represents the mean
of 6 diffusion chambers + s.e.
in Ham's F12 medium for 12 h before
irradiation (Fig. 1).
Fig. 2 shows the invitroirradiationdose-
response curve for the melanoma xeno-
graft (HX47) compared with the results of
one experiment in which cryopreserved
cells from the original biopsy sample
(Patient A) were irradiated under similar
conditions. The xenograft data yield a
Do value of 1'24 Gy (confidence limits
1*01-1.63) with an extrapolation number
of 10; the data for the cryopreserved cells
do not differ significantly.
Treatment of cryopreserved cells from
Patient C and cells from HX49 with
Adriamycin and cyclophosphamide in the
ADC system produced the cell-survival
curves in Fig. 3. The lines appear to be
exponential, passing near to the origin,
and were analysed by logarithmic regres-
sion analysis. Although the cells ofPatient
C seemed slightly more sensitive than
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Fic. 2. Cell surxival after in vitro irradiation
of cells from lhuman melanoma metastasis
(Patient A) (0) and the corresponding
xenograft HX47 (0). Points represent the
mean of 6 chambers + s.e.
those from the xenograft, the difference
is not statistically significant. On the basis
of the few data points obtained for
Adriamycin, the xenograft and cryo-
preserved cells were similarly sensitive.
DISCUSSION
In a moderately extensive study of more
than 40 human tumour biopsy samples, a
high proportion were found to form colo-
nies in soft agar (Courtenay et al., 1978,
andunpublished). However, only 3samples
were obtained which yielded adequate
numbers ofviable cells in suspension, grew
in the ADC assay with PE >10,% and were
available in sufficient quantities to allow
direct cloning, cryopreservation, xeno-
grafting and reproducible cell survival
studies. The data in the present report
0.1t
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FIG. 3. Cell survival after treatment in
ADC of cells from Patient C. Open symbols
indicate cryopreserved cells; closed sym-
bols xenografted cells (HX49). Mean of 6
clhambers + s.e. Treatment with cyclo-
phosphamide (0, *) or with Adriamycin
(A, AL)-
are therefore limited, and only tentative
conclusions can be drawn. However, it
appears that the ADC systemn provides a
means of studying clonogenic cell survival
in human tumours without prior adapta-
tion to growth in experimental conditions.
Cryopreservation did not reduce the PE
of the tumours, and it allowed an assess-
ment of the reproducibility of results. In
an earlier study (Selby et al., 1980)
melanoma xenografts that had been re-
established after cryopreservation were
found not to have changed their chemo-
sensitivity to 3 different drugs.
The shapes of the dose-response curves
after in vitro irradiation of cryopreserved
human tumour cells were of the typical
shoulder-exponential type described for
mammalian cells. The parameters of the
curves are within the range found for
experimental animal tumours, human
cell lines and human tumour xenografts
(Hall, 1978; Smith et al., 1978; Guichard
et al., 1977). Radiation dose-response
curves have not previously been reported
146SURVIVAL O(F CRYOPRESERVED TUMOUR CELLS 147
for human tumour cells without an inter-
mediate stage of tissue culture or growth
as xenografts. The exponential curve for
cyclophosphamide is also compatible with
studies using this drug to treat animal
tumours, cell lines and human tumour
xenografts (Smith et al., 1976; Hill &
Stanley, 1979; van Putten & Lelieveld,
1970). There were insufficient data for
Adriamycin to allow conclusions about the
shape of the dose-response curve.
The similarity between the responses of
cryopreserved cells and xenografted cells
to irradiation, cyclophosphamide and
Adriamycin supports the hypothesis that
xenografting does not substantially alter
the inherent sensitivity of tumour cells to
treatment, at least in early passages.
Cryopreservation has important technical
advantages when dealing with cells that
have a low and unpredictable PE. As used
here it allows the drug sensitivity of
tumours to be compared with their xeno-
grafts using the same endpoints for each,
and with the same activation and metabo-
lism of the drug under test. As a way of
evaluating xenografts it may be comple-
mentary to the conventional approach of
comparing xenograft responses measured
by tumour-volume changes with clinical
responses in the patient.
The ADC system for the treatment of
cells with drugs is highly artificial, in
particularbecauseoftheisolationoftreated
cells from each other and the absence of a
tumour stroma. However, we have found
with a number of melanoma xenografts
that the sensitivity to melphalan, methyl-
CCNU, DTIC and Adriamycin was often
the same whether the cells were exposed
as a xenograft or in the ADC system; in a
few cases the ADC-exposed cells were more
sensitive, as found by Smith & Gordon
(1978). The advantages of ADC exposure
over alternative in vitro methods for the
treatment of human tumour cells are that
it allows for in vivo drug activation and the
in vivopharmacokinetics ofthedrugsunder
test. Studies in our own laboratory (Bate-
man et al., 1980) and others (Ogawa et al.,
1973) support the suggestion that in vitro
drug testing can predict in vivo tumour
responses in animal tumours and human
tumour xenografts, but these have been
restricted to drugs that are not thought to
require in vivo activation.
The PE of tumours in this study and in
those of other groups are low, which sug-
gests the possibility that atypical sub-
populations of cells are being grown and
treated, leading to erroneous estimates of
the sensitivity ofthe whole tumour (Ham-
burger & Salmon, 1977; Courtenay et al.,
1978). This possibility is reduced by the
similarity of the results for xenografted
tumours which had higher PEs, and also
by the observation that results were
similar for xenograft tumours when
colonies were grown under widely differing
conditions in a lung colony assay (Selby
& Thomas, 1980).
The ADC system is expensive and
labour-intensive when compared to in
vitro cloning assays. Xenografting and
cryopreservation oftumours and examina-
tion only of those with PE > 1% places
limits upon the number of tumours which
may be studied. However, the combination
ofthese approaches with the simpler, more
direct methods which are being developed,
may lead to reliable estimation of the
sensitivities of clonogenic tumour cells to
cytotoxic treatments.
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